Merck Wins Second Fosamax Trial After Questioning Qualifications Of Expert Witness
This article was originally published in The Pink Sheet Daily
Executive Summary
After two bellwether cases, Merck has yet to lose and the next case involves a company-chosen defendant.
You may also be interested in...
Merck, Hit With First Fosamax Verdict, Challenges Plaintiff's Closing Arguments
Firm hopes to negate $8 million verdict through post-trial motions.
Merck, Hit With First Fosamax Verdict, Challenges Plaintiff's Closing Arguments
Firm hopes to negate $8 million verdict through post-trial motions.
Must Sponsors Announce All Adverse Events To Avoid Securities Lawsuits?
Do drug makers have to disclose any possible drug-related injuries to avoid a securities action